Latest Ratios: P/E Ratio -0.6x · EV/EBITDA N/A · ROE -78.6%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $5M | $740M | $32M | $98M | — | — |
| Enterprise Value | $-108111 | $331329 | $733M | $32M | $95M | — | — |
| P/E Ratio → | -0.56 | — | — | — | — | — | — |
| P/S Ratio | 290.52 | 320.16 | 21204.54 | 1850.92 | 103366.74 | — | — |
| P/B Ratio | 0.52 | 0.68 | 77.41 | 10.68 | 22.83 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 22.35 | 21007.99 | 1849.60 | 99926.22 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | -43737.5% | -43737.5% | -23977.9% | -42440.4% | -478784.3% | -68862.2% | — |
| Net Profit Margin | -43832.5% | -43832.5% | -24028.2% | -49087.8% | -490630.0% | -68862.2% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -78.6% | -78.6% | -134.0% | -230.8% | -173.6% | -110.0% | -1002.5% |
| ROA | -70.7% | -70.7% | -111.2% | -156.4% | -126.8% | -80.1% | -135.6% |
| ROIC | -185.0% | -185.0% | -222.7% | -273.7% | -429.5% | -245.8% | — |
| ROCE | -75.6% | -75.6% | -123.0% | -182.8% | -169.4% | -110.0% | -1009.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.10 | 0.43 | 0.20 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.63 | -0.72 | -0.01 | -0.76 | -0.48 | -3.93 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -438.04 | -438.04 | -448.76 | -0.24 | — | — | — |
Net cash position: cash ($5M) exceeds total debt ($695619)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 9.79 | 9.79 | 13.92 | 3.29 | 3.02 | 23.71 | 0.64 |
| Quick Ratio | 9.79 | 9.79 | 13.92 | 3.29 | 3.02 | 23.71 | 0.64 |
| Cash Ratio | 8.45 | 8.45 | 12.39 | 1.53 | 2.11 | 15.13 | 0.61 |
| Asset Turnover | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 200.07 | 194.71 | 106.09 | — | 365.00 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $2M | $27M | $422837 | $3M | $317158 | $10M |
Capital exhaustion and dilution
As reported in financial filings, CDIO trades at a P/S multiple of 280.74, a figure that appears disconnected from the company's negligible TTM revenue of $14,825 and suggests that market participants are pricing the firm as a speculative R&D option rather than a commercial diagnostic entity.
The extreme P/S ratio indicates that investors are not valuing the company based on current output, but rather on the potential terminal value of its intellectual property. This valuation level warrants caution, as it implies an expectation of a transformative event or acquisition that is not currently supported by the company's clinical adoption trajectory.
Based on reported figures, the company's ROIC has remained deeply negative, fluctuating between -37.2% and -113.9% over the last ten quarters, which highlights a structural inability to generate returns on invested capital while the firm continues to consume resources to maintain its laboratory infrastructure.
The consistent decay in ROIC suggests that the capital deployed into the business is failing to produce meaningful economic value. Investors should monitor whether management can pivot toward a more efficient model, as the current trend indicates that every dollar of capital invested is currently eroding shareholder value rather than compounding it.
According to recent SEC filings, the company's asset turnover remains effectively at 0.00, reflecting a lack of meaningful revenue generation relative to the asset base and suggesting that the firm's current operational scale is insufficient to drive any measurable efficiency in its working capital cycle.
The erratic nature of the Days Sales Outstanding (DSO) metric, which has swung from 46 to over 1,300 in recent periods, implies significant instability in the collection process or, more likely, the impact of sporadic, low-volume transactions. This lack of operational rhythm makes it difficult to assess the company's true ability to manage customer leverage or optimize its cash conversion cycle.
As reported in financial statements, the current ratio has shown extreme volatility, ranging from 3.29 to 23.55, which suggests that the company's liquidity position is heavily dependent on the timing of capital raises rather than a stable, self-sustaining operational cash flow profile.
While the high current ratio might appear superficially healthy, it is largely a function of cash on hand rather than operational liquidity. The rapid depletion of this cash buffer, combined with the lack of revenue, suggests that the company remains highly vulnerable to liquidity stress if it cannot secure additional financing in the near term.
The most commonly misapplied metric for CDIO is the P/S ratio, which obscures the company's lack of commercial-stage revenue and fails to account for the fact that the firm is currently operating as a distressed R&D project rather than a mature diagnostic business.
Using standard diagnostic industry multiples for CDIO is misleading because the company lacks the reimbursement tailwinds and clinical volume that underpin the valuations of its peers. Analysts should instead focus on the 'Cash Burn Runway' and the strategic value of the underlying epigenetic data, as these metrics provide a more accurate assessment of the company's survival and potential M&A attractiveness.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CDIO stock.
Cardio Diagnostics Holdings, Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
Cardio Diagnostics Holdings, Inc.'s return on equity (ROE) is -78.6%. The historical average is -145.4%.
Based on historical data, Cardio Diagnostics Holdings, Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Cardio Diagnostics Holdings, Inc. has 100.0% gross margin and -43737.5% operating margin.